CLDX - Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis

CLDX Celldex reports results from phase 2 study of barzolvolimab in prurigo nodularis Celldex Therapeutics - phase 2 study of barzolvolimab in prurigo nodularis did not meet key efficacy objectives - Phase 3 csu topline data expected Sept/oct 2026; phase 3 sd and coldu enrollment on track - Discontinues phase 2 study of barzolvolimab in prurigo nodularis